<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868799</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201123</org_study_id>
    <nct_id>NCT04868799</nct_id>
  </id_info>
  <brief_title>Finding New Targets by Proteomic Approaches (InnovRT1)</brief_title>
  <acronym>InnovRT1</acronym>
  <official_title>Heterogeneity in Rhabdoid Tumors : Proteomic and Single-Cell Analyses to Identify New Therapeutic Targets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sainte Anne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to explore the inter tumor heterogeneity by a proteomic approach of a&#xD;
      wide series of rhabdoid tumors, from both intra and extra cranial origins.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Context: Rhaboid tumors (RT) are aggressive cancers of young infants, exposed to the toxicity&#xD;
      of heavy treatments often ineffective, which justifies the need to identify new treatment&#xD;
      strategies. These tumors are characterized by the biallelic alteration of SMARCB1 gene,&#xD;
      encoding one of the subunits of the SWI/SNF complex, a chromatin remodeler. These mutations&#xD;
      are the only ones found in these very stable cancers, which offers few therapeutic targets&#xD;
      that can be identified by genomic techniques. They are morphologically undifferentiated and&#xD;
      pluriphenotypic, suggesting the existence of a cellular diversity still poorly described. To&#xD;
      advance on these questions, the investigators' laboratory has developed a model of&#xD;
      genetically engineered mouse model spontaneously developing RT, biologically very similar to&#xD;
      their human counterparts.&#xD;
&#xD;
      Objectives and methods: The investigators' project aims to describe the proteomic and&#xD;
      phosphoproteomic signatures of these tumors, so far described at the genome and transcriptome&#xD;
      level; an integration of these pangenomic / pan-proteomic studies will reveal the most&#xD;
      relevant features to target. The investigators will fully characterize the proteomic and&#xD;
      phosphoproteomic landscape using mass spectrometry on a cohort of clinically, radiologically&#xD;
      and histopathologically annoted ATRT, for which methylome and RNAseq profiling will also be&#xD;
      done. The investigators will describe the proteomic features of each molecularly defined&#xD;
      subgroups, and aim to correlate RNAseq changes with proteomic features.&#xD;
&#xD;
      Patients will be included if they or their legal representative have given a consent to such&#xD;
      a study, and if frozen material is stored at Necker Hospital.&#xD;
&#xD;
      Expected results: This analysis helps to identify how to articulate several innovative&#xD;
      therapeutic approaches, taking into account both the diversity of the cells to be treated,&#xD;
      and the real targets, proteins, to inhibit or restore.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of proteomic signature for each molecular subgroup of ATRT</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>ATRT</condition>
  <arm_group>
    <arm_group_label>ATRT</arm_group_label>
    <description>Patients &lt;18 years with an ATRT having frozen samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mass spectrometry</intervention_name>
    <description>Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry</description>
    <arm_group_label>ATRT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        cohort of clinically, radiologically and histopathologically annoted ATRT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 0-17 years old&#xD;
&#xD;
          -  Rhabdoid tumor, treated in oncology departments in Ile de France&#xD;
&#xD;
          -  frozen samples collected in usual care&#xD;
&#xD;
          -  parents' agreement for samples collection in usual care&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Unconfirmed diagnosis of Rhabdoid tumor with molecular analyses Samples&#xD;
&#xD;
          -  paraffin embedded tissues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Beccaria, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>APHP Assistance Publique des H么pitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck BOURDEAUT, MD</last_name>
    <phone>01 44 32 44 71</phone>
    <email>franck.bourdeaut@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly BRIAND, PhD</last_name>
    <phone>01 44 38 18 62</phone>
    <email>nelly.briand@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de neurochirurgie - H么pital Necker Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck BOURDEAUT, MD</last_name>
      <phone>01 44 32 44 71</phone>
      <email>franck.bourdeaut@curie.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SMARCB1</keyword>
  <keyword>ATRT</keyword>
  <keyword>Brain Tumors</keyword>
  <keyword>Proteomic</keyword>
  <keyword>Multi-omics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

